Boost Biomes closes $5 million Series A and JDA with Yara

June 30, 2020
Emerging Ecosystems in Agrifood and Health More...
Investment More...
Very important

Yara's $3 million equity investment was joined by Viking Global Investors and Y Combinator, pushing Boost's funding to $10 million. The round accelerates the commercial development of its microbial biofungicides. Boost pairs discovery and microbial enrichment platforms with decentralized biofermentation from Cultural Biosciences to speed development. Yara's investment is timely given Boost's 2019 patent application for its tech. The JDA will focus on nutrient use efficiency for likely synergy with Yara's seed treatments. Clients, expect Yara to bring its strong agronomic and plant- and soil-monitoring solutions to the table to validate products in the field. Consider a similar model toward developing bio-based synergy in crop nutrition. 

For the original news article, click here .

Further Reading

Crop Enhancement raises $8 million Series B to support co-development initiatives with agrichemical companies

News Commentary | April 16, 2020

The funding round, led by Spruce Capital Partners and joined by 1955 Capital, Phoenix Venture Partners, Cavallo Ventures, Davinia Investment, and Alexandria Ventures, builds on its 2017 $8.5 million Series A. Crop Enhancement develops coatings for pre‑ and post‑harvest applications formulated from ... Not part of subscription

AI-driven crop protection discovery startup Enko Chem raises $45 million Series B

News Commentary | June 26, 2020

Led by the Bill & Melinda Gates Foundation and joined by six other investors, the round brings Enko Chem's total funding to $66 million in three years. Enko will advance its discovery efforts toward finding alternatives to existing insecticides, fungicides, and herbicides. Enko's discovery ... To read more, click here.

Israeli startup Ukko raises $40 million Series B for its "food as medicine" applications

News Commentary | February 01, 2021

This Series B round was led by Bayer's CVC arm, Leaps by Bayer, and brings Ukko's funding raised to date to $47.5 million. The company's technology leverages computational biology and synthetic biology approaches, including genome editing, to identify and engineer proteins related to food allergies... Not part of subscription